Financial analysis of McKesson

McKesson’s FY2026 results paint a picture of a company that appears to be reaping the benefits of its strategic pivot toward higher-value services, while maintaining the immense scale of its core distribution business. Revenue reached $403.4 billion, a 12.4% increase over the prior year, and net income attributable to McKesson surged 44.5% to $4.76 billion. The combination of solid top‑line expansion and even faster profit growth suggests that operational leverage and mix improvements are taking hold, though the persistently negative shareholders’ equity remains a defining feature of the financial profile.

The revenue growth was broad‑based, but the Oncology & Multispecialty segment stood out with a 31% jump to $48.4 billion, reinforcing the company’s emphasis on higher‑margin specialty areas. While overall gross margins remain razor‑thin at roughly 3.6%—typical for pharmaceutical wholesale—the operating margin expanded notably from 1.23% to 1.54%. This improvement appears to be driven less by gross margin gains and more by a striking reduction in selling, general, and administrative expenses, which fell by about $400 million despite the higher volumes. A swing from net litigation charges to a small credit and slightly lower restructuring costs also contributed, pushing net margin to 1.18%, a level not seen in the five‑year history provided.

The balance sheet reflects a company simultaneously investing in growth and returning large sums to shareholders. Total assets grew 9.6% to $82.3 billion, with a sharp increase in intangible assets and goodwill following $3.4 billion in acquisitions. On the other side, treasury stock deepened to a negative $32 billion, further entrenching the shareholders’ deficit. Liquidity metrics such as a current ratio of 0.85 and a quick ratio of 0.49 point to a business model that relies heavily on supplier financing, yet the net cash position—where cash and equivalents exceed total debt—may temper concerns about the negative equity.